Bio-Techne Corp (STU:TE1)
€ 69.5 0 (0%) Market Cap: 11.07 Bil Enterprise Value: 11.27 Bil PE Ratio: 80.74 PB Ratio: 5.63 GF Score: 95/100

Q4 2024 Bio-Techne Corp Earnings Call Transcript

Aug 07, 2024 / 01:00PM GMT
Release Date Price: €72 (-1.37%)

Key Points

Positve
  • Bio-Techne Corp (TECH) reported 1% year-over-year organic revenue growth in a challenging fiscal year.
  • The company saw mid-single digit growth in its Simple Plex and Simple Western platforms, with double-digit growth in related consumables.
  • The cell and gene therapy vertical experienced mid-single digit growth and added more customers.
  • The molecular diagnostics growth vertical achieved double-digit growth, driven by new product launches and ongoing traction.
  • Bio-Techne Corp (TECH) maintained a strong balance sheet with $151.8 million in cash and a total leverage ratio well below one times EBITDA.
Negative
  • The company faced a challenging funding environment for biotech and significant R&D budget recalibration by large pharma and academia customers.
  • North America and Europe both declined low single digits in the quarter, reflecting constrained biopharma and academic end markets.
  • China declined high single digits in the fourth quarter, in line with expectations but still a negative impact.
  • Adjusted EPS decreased to $0.49 from $0.55 in the prior year quarter, with foreign exchange having a material impact.
  • Adjusted operating margin for Q4 was 33.5%, a decrease of 360 basis points from the prior year period.
Editor Bio;Techne Corporation;Editor

Please stand by for streaming text No, no, no, no, no. No, no, no, no, no. Until then?

Yes, the furnaces, the operating room to in So half of oh four to all. Fair enough. First Phone over the past in full. Fair and Thanks, Bill. Perfect further that effort. No. The first mover. Fair enough. Thanks, turnover.

Operator

For Good morning and welcome to the Bio-Techne Earnings Conference Call for the Fourth Quarter of Fiscal Year 2024. At this time, all participants have been placed in a listen-only mode and the call for questions. Following management's prepared remarks during our Q&A session, please limit yourself to one question and one follow-up. I would now like to turn the call over to David Clair, Bio-Techne's Vice President of Investor Relations.

David Clair
Bio-Techne Corporation - Senior Director of IR & Corporate Development

Good morning and thank you for joining us. On the call with me this morning are Jim children and President and Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot